FASEB Conference: Genome Engineering: Research and Applications

The Federation of American Societies for Experimental Biology (FASEB) conference on Genome Engineering kicks off one month from now in Rome, Italy.

By: Karen O'Hanlon Cohrt - May. 7, 2024
News

The Federation of American Societies for Experimental Biology (FASEB) conference on Genome Engineering kicks off in Rome, Italy on the 16th June with David Liu as keynote speaker. Running until the 20th June, the event will focus on the field of genome and epigenome editing, showcasing new genome-editing tools and technologies, as well as advances in our understanding the biology of gene editors and their outcomes.

In addition, new classes of precise editors will be introduced, clinical trials of genome editors will be discussed, and plant and animal modelling with precise genome editing will be presented. The event will also feature workshops to share expertise in genome editing as well as a panel discussion about career development.

The conference seeks to present the latest research findings within the genome-editing field as well as support early-career investigators, women, and other historically-excluded groups in this field. The organisers, which includes Shengdar Q. Tsai, PhD (Associate Member, St. Jude Children’s Research Hospital, Memphis, TN) Nicole Gaudelli, PhD (Entrepreneur in Residence at Google Ventures, Cambridge, MA), Philip Gregory, PhD (CSO, 2Seventy Bio), and Angelo Lombardo, PhD (Assistant Professor, Università Vita-Salute San Raffaele, Milan, Italy) encourage scientists from all countries and institutions with shared interests in genome and epigenome editing to join FASEB and their volunteer organisers in Rome, Italy for stimulating presentations, discussions, and activities.

Registration closes on the 11th June. See the conference website here for further details.

Tags

HashtagArticleHashtagNews

News: FASEB Conference: Genome Engineering: Research and Applications
CLINICAL TRIALS
IND Enabling
Phase I
Phase II
Phase III
Primary Open Angle Glaucoma, POAG, (NCT06465537)
Sponsors:
Shanghai BDgene Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine